Nolva-20

Description

Nolva-20 Description

Introducing Nolva-20, a premium antiestrogenic supplement from the renowned Core Labs / Revange brand. This formulation is designed for those looking to effectively manage estrogen levels while simultaneously enhancing testosterone production.

Mechanism of Action:
Once ingested, Nolva-20’s active ingredient is promptly absorbed in the intestine. It binds to plasma albumin and travels throughout the body. The mechanism of action involves competing with estrogen for binding to the estrogen receptor sites, effectively blocking the hormone from exerting its typical actions in various tissues. This blockade is instrumental not only in managing estrogen-related effects but also in promoting a balanced hormonal environment conducive to testosterone production.

In addition to its anti-estrogen properties, Nolva-20 has been observed to:

• Reduce blood levels of total cholesterol and low-density lipoprotein (LDL), supporting cardiovascular health.
• Help maintain bone mineral density, offering protective benefits against conditions like osteoporosis.

Moreover, Nolva-20’s unique ability to counteract the negative feedback loop caused by elevated estrogen levels results in increased stimulation of the hypothalamus and pituitary gland. This leads to a notable surge in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), both critical hormones involved in the natural production of testosterone.

Dosage:
For optimal results, it is recommended to take 1 capsule daily, each containing 20 mg of the active ingredient.

Contents:
– Each capsule contains:
– Active Ingredient: Tamoxifen Citrate (20 mg)
– Inactive Ingredients: Gelatin, Microcrystalline Cellulose, Magnesium Stearate, and Silicon Dioxide.

Conclusion:
Experience the benefits of effective estrogen management with Nolva-20 by Core Labs / Revange, an essential tool for those seeking to enhance their hormonal balance and promote natural testosterone production. Always consult a healthcare professional before beginning any new supplement regimen.

1. Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer–survival or death? J Clin Oncol. 2008;26(18):3073-3082. doi:10.1200/JCO.2008.17.5190
2. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937-947. doi:10.1046/j.1525-1497.2003.20724.x
3. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852-856. doi:10.1056/NEJM199203263261302
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388. doi:10.1093/jnci/90.18.1371
5. O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90(12):2317-2325. doi:10.1038/sj.bjc.6601879
6. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-2139. doi:10.1016/S0140-6736(02)09088-8
7. Cuzick J, Sestak I, Baum M,